According to the results of 2022 Lekhkim-Kharkiv Pharmaceutical Company (Kharkiv) increased its net profit by 5.92% in comparison with 2021 – up to UAH 105.279 million.
As the company announced in the information disclosure system of the National Securities and Stock Market Commission, its shareholders will consider the results of its work at a general meeting on April 20.
It is planned to make a decision that the net profit for 2022 will be used for the development and financing of the company’s activity.
Earlier it was reported that in 2021 Lekhkim-Kharkiv increased net profits by 25% compared to 2020 – up to 99.9396 million UAH.
According to the NCSSM information disclosure system, 98% of Lekhkim-Kharkiv PJSC shares are owned by Lekhim PJSC (Kiev), the beneficiary of which is Valery Pechav.
“Lekhkim-Kharkiv” produces medicines in different dosage forms: tablets, ampoules, suppositories, solutions for infusion, solutions for injections, powders for injection solution, sachets. It is part of the Lekhim group of companies.
